Compare Ascendis Pharma A/S (ASND) vs Nano Dimension Ltd - ADR (NNDM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Nano Dimension Ltd - ADR — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Nano Dimension Ltd - ADR trades at $1.48 (market cap $314.71M). The key difference: Ascendis Pharma A/S is far larger — about 56.4× Nano Dimension Ltd - ADR's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Nano Dimension Ltd - ADR nearer its low. Which is the better fit depends on your goals.
| ASND | NNDM | |
|---|---|---|
Market Cap | $17.74B | $314.71M |
Sector | Health | Technology |
52-Week High | $277.18 | $2.14 |
52-Week Low | $163.32 | $1.21 |
Enterprise Value | $18.11B | -$94.63M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Nano Dimension (NNDM) trades at $1.50, showing no daily change. The technical signal is mixed with a bullish overall signal but bearish moving averages. Fundamentally, the company reported revenue growth to $102.44M in 2025, but net losses deepened to -$293.30M, with a negative net income margin of -286.72%. Recent news highlights boardroom disputes with shareholder Murchinson and a proposed business combination with Infinite Epigenetics.
The outlook remains challenging due to persistent losses and negative cash flow, though the low P/B ratio of 0.65 may attract value investors. Key risks include execution of strategic plans, shareholder activism, and achieving profitability. Analyst sentiment is cautious given the financial performance and corporate governance concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →
